Domark International (DOMK) 10-Q 14 Apr 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Feb. 28, 2014
Document And Entity Information	'
Entity Registrant Name	'Domark International Inc.
Entity Central Index Key	'0001365160
Document Type	'10-Q
Document Period End Date	28-Feb-14
Amendment Flag	'false
Current Fiscal Year End Date	'--05-31
Is Entity a Well-known Seasoned Issuer?	'No
Is Entity a Voluntary Filer?	'No
Is Entity's Reporting Status Current?	'Yes
Entity Filer Category	'Smaller Reporting Company
Entity Common Stock, Shares Outstanding	176,200,562
Document Fiscal Period Focus	'Q3
Document Fiscal Year Focus	'2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Feb. 28, 2014	31-May-13
CURRENT ASSETS	'	'
Cash and cash equivalents	'	$20
Loan receivable from consultant	36,203	'
Prepaid expenses	14,176	17,823
TOTAL CURRENT ASSETS	50,379	17,843
INVESTMENTS	1,123,308	'
OTHER ASSETS	'	'
Patents, net of accumulated amortization of $1,000 and $0, respectively	74,500	40,000
Licenses, net of accumulated amortization of $2,898 and $1,828, respectively	307,102	8,182
TOTAL OTHER ASSETS	381,602	48,182
TOTAL ASSETS	1,555,289	66,025
CURRENT LIABILITIES	'	'
Bank overdraft	56	'
Note payable to bank	180,000	'
Accounts payable & accrued expenses	257,285	209,179
Amounts due under Licensing Agreement with Wazzamba SA	300,000	'
Loans payable to consultants and stockholders	207,995	45,288
Convertible notes payable (net of unamortized discounts of $458,701 and $59,301, respectively)	186,849	148,691
Derivative liability for convertible notes payable	1,040,197	237,578
TOTAL CURRENT LIABILITIES AND TOTAL LIABILITIES	2,172,382	640,736
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series A convertible preferred stock - issued and outstanding 50,000 shares	50	50
Common stock, $0.001 par value, authorized 900,000,000 shares: 301,021,000 & 179,435,000 issued, & 176,200,562 and 54,615,298 shares outstanding, respectively	301,021	179,435
Less: Treasury Stock	-124,820	-124,820
Common stock payable	858,000	858,000
Additional paid-in capital	42,999,670	40,816,440
Accumulated deficit	-26,850,830	-26,850,830
Accumulated deficit during development stage	-17,800,184	-15,452,986
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	-617,093	-574,711
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$1,555,289	$66,025

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Feb. 28, 2014	31-May-13
Consolidated Balance Sheets Parenthetical	'	'
Patents, net of accumulated amortization	$1,000	$0
License, net of accumulated amortization	2,898	1,828
Convertible notes payable net of unamortized discounts	$458,701	$59,301
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Preferred stock series A, par value	$0.00	$0.00
Preferred stock series A, shares authorized	10,000,000	10,000,000
Preferred stock series A, shares issued	50,000	50,000
Preferred stock series A, shares outstanding	50,000	50,000
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	900,000,000	900,000,000
Common Stock, shares issued	301,021,000	179,435,000
Common Stock, shares outstanding	176,200,562	54,615,298

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		52 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
Consolidated Statements Of Operations	'	'	'	'	'
Sales	'	$1,396	'	$37,934	$57,864
Cost of sales	'	483	'	29,624	80,284
Gross profit	'	913	'	8,310	-22,420
Operating expenses:	'	'	'	'	'
General and administrative	438,528	224,077	759,904	763,374	2,432,786
Stock-based compensation - consultants	'	173,647	453,825	609,697	5,545,583
Stock-based compensation - Salaries & wages	'	224,077	257,476	'	2,033,234
Research and development	'	'	'	'	45,609
Amortization of Barefoot-Science license fee	'	500,000	'	1,394,520	1,394,520
Impairment of Barefoot-Science license fee	'	4,605,480	'	4,605,480	4,605,480
Depreciation expense	1,360	360	2,080	3,343	16,621
Impairment of other assets	'	'	'	'	20,000
Bad debt expenses	'	'	'	1,456	101,456
Loss (income) on settlement of debt	'	'	'	-24,197	409,903
Total operating expenses	439,888	5,761,010	1,473,285	7,882,530	16,605,192
Loss from operations	-439,888	-5,760,097	-1,473,285	-7,874,220	-16,627,612
Other income (expense):	'	'	'	'	'
Other income	'	'	'	'	29,567
Revaluation of derivative liability for convertible notes	-342,625	-17,256	-504,369	-17,256	-741,947
Currency translation loss	-18,569	'	-18,569	'	-18,569
Interest expense	-262,972	-3,685	-350,975	-38,715	-441,623
Total other income (expense)	-621,166	-20,941	-873,913	-55,971	-1,172,572
Net loss	($1,064,054)	($5,781,038)	($2,347,198)	($7,930,191)	($17,800,184)
Net loss per common share, basic and diluted	($0.01)	($0.19)	($0.02)	($0.27)	'
Weighted average common shares outstanding	138,202,346	29,708,038	96,680,371	29,553,176	'

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (Unaudited) (USD $)	9 Months Ended		52 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net Loss	($2,347,198)	($7,930,191)	($17,800,184)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	2,080	3,343	16,621
Amortization of deferred finance costs	'	24,799	60,000
Common stock issued as compensation	513,675	1,138,554	7,381,191
Non cash interest expense	336,064	2,955	341,709
Loss (gain) on derivative valuation	504,369	17,256	741,947
Amortization of prepaid license fees	'	1,394,520	1,394,520
Impairment of assets	'	4,605,480	4,615,480
Loss (income) on settlement of debt	'	-24,197	409,903
Changes in Operating assets and liabilities:	'	'	'
Inventory - tv production	'	'	-16,926
Prepaid expenses	3,647	-23,830	-9,279
Accounts payable and accrued expenses	48,162	449,783	426,645
Accounts payable -related party	'	8,831	15,366
Net cash used in operating activities	-939,257	-332,697	-2,423,062
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Cash paid for licensing	'	'	-35,000
Cash paid for furniture & equipment	'	'	-4,000
Cash Paid for web development	'	'	-7,500
Cash paid for investments	-171,608	'	-171,608
Cash paid for loan receivable from consultant	-36,203	'	-36,203
Net cash used in investing activities	-207,811	'	-254,311
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from convertible notes payable	752,500	50,000	862,500
Proceeds from loans payable to consultants and stockholders	224,499	193,288	1,312,187
Payments made on loans payable to consultants and stockholders	-10,007	-1,000	-136,485
Proceeds received from notes payable	180,000	43,558	736,058
Payments made on notes payable	'	'	-100,470
Net cash provided by financing activities	1,146,992	285,846	2,673,790
Net increase(decrease) in cash and cash equivalents	-20	-46,851	-3,527
CASH BALANCE BEGINNING OF PERIOD	20	52,269	3,527
CASH BALANCE END OF PERIOD	'	5,418	'
Cash paid for interest	9,700	'	'
Cash paid for taxes	'	'	'
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:	'	'	'
Licensing Agreement with Wazzamba SA in exchange for amounts due under Licensing Agreement with Wazzamba SA	300,000	'	300,000
Prepaid licensing fee	'	6,000,000	6,000,000
Shares issued for settlement of loans payable to consultants and stockholders	52,500	'	52,500
Shares issued for settlement of convertible notes payable	475,664	'	623,664
Shares issued for patent acquisition	35,500	'	75,500
Shares issued for equity interest in Imagic Ltd	796,700	'	796,700
Convertible notes payable issued for equity interests in Imagic Ltd.	$150,000	'	$150,000

Description_of_Business

Description of Business	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 1 - Description of Business	'
	DOMARK INTERNATIONAL, INC. ("DoMark" or the "Company") was incorporated under the laws of the State of Nevada on March 30, 2006. During 2008 and 2009, the Company acquired several operating businesses. On May 21, 2009, the Company entered into an acquisition agreement (the "Victory Lane Agreement") with Victory Lane Financial Elite, LLC ("Victory Lane") with respect to a real estate lifestyle business known as "Victory Lane" (the "Victory Lane Business"). Shortly thereafter, a dispute arose between the Company and the principals of Victory Lane regarding the representations of the principals of Victory Lane and the Victory Lane Business and the Victory Lane Agreement.
	On March 5, 2012, the Company entered into an Asset Purchase Agreement with its then controlling shareholder, R. Thomas Kidd, for the sale of the Company’s subsidiary Armada Armada/The Golf Championships and certain assets related thereto. The Company relied upon Accounting Standards Codification (“ASC”) Topic Nos, 860-20-25 and 860-20-40 to record the sale. The fair value of the transaction was measured at the fair value of the assets less any liabilities sold.
	On February 29, 2012, the Company formed a new wholly owned subsidiary, Solarwerks, Inc. in the state of Nevada, for the purposes of entering the business of marketing specialized solar consumer electronics. Solarwerks' current focus is to develop and distribute the SolaPad, a combined cover and charging system for Apple's iPad; and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone. Solarwerks competes in a market that also includes 3D Systems (DDD), Dell (DELL) and Hewlett Packard (HPQ). Solarwerks, Inc. is currently in default with the Nevada Secretary of State.
	On June 20, 2012, the Company formed a new wholly-owned subsidiary, MuscleFoot Inc. in the state of Nevada for the purpose of distributing, marketing, and acting as sales agent for the patented foot care system of Barefoot Science. MuscleFoot Inc. is currently in default with the Nevada Secretary of State.
	On July 20, 2012, the Company formed a new wholly-owned subsidiary, DoMark Canada Inc. in the province of Ontario for the purpose of supporting the Company’s corporate operations based in Toronto, Ontario, Canada.
	On February 28, 2013, the Company entered into a Memorandum of Understanding to purchase 44% of Zaktek Ltd. (“Zaktek”). Zaktek’s main product is the phonepad+, an Apple Inc. approved tablet device that works with smartphones, including the Apple iPhone® and Samsung Galaxy products to improve functionality including video and gaming abilities.
	On April 23, 2013, the Company received notification that Zaktek was ending discussions in regards to the definitive purchase agreement with DoMark.
	On June 11, 2013, the Company then purchased 100% of South Hill Ltd., an English private limited company, which owns approximately 19% of Zaktek.

Going_Concern

Going Concern	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 2 - Going Concern	'
	The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America which contemplate continuation of the Company as a going concern. For the period October 21, 2009 (inception of development stage) to February 28, 2014, the Company incurred losses from operations of $17,800,184. Furthermore, the Company has inadequate working capital to maintain or develop its operations, and is dependent upon funds from private investors and the support of certain stockholders.
	These factors raise substantial doubt about the ability of the Company to continue as a going concern. These condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. In this regard, management is planning to raise any necessary additional funds through loans and additional sales of its common stock. There is no assurance that the Company will be successful in raising additional capital.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 3 - Basis of Presentation	'
	The unaudited condensed consolidated financial statements as of February 28, 2014 and for the three and nine months ended February 28, 2014 and 2013 have been prepared in accordance with accounting principles generally accepted in the United States for interim condensed consolidated financial information and with instructions to Form 10-Q. In the opinion of management, the unaudited condensed consolidated financial statements have been prepared on the same basis as the annual condensed consolidated financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the condensed consolidated financial position as of February 28, 2014 and the results of operations and cash flows for the three and nine months ended February 28, 2014 and 2013. The financial data and other information disclosed in these notes to the interim condensed consolidated financial statements related to these periods are unaudited. The results for the nine month period February 28, 2014 are not necessarily indicative of the results to be expected for any subsequent quarter of the entire year ending May 31, 2014. The condensed consolidated balance sheet at May 31, 2013 has been derived from the audited condensed consolidated financial statements at that date.
	Certain information and footnote disclosures normally included in condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission’s rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended May 31, 2013 as included in our report on Form 10-K.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 4 - Summary of Significant Accounting Policies	'
	RECENT ACCOUNTNG PRONOUNCEMENTS
	The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. It does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows.
	DEVELOPMENT STAGE COMPANY
	The Company is a development stage company as defined in ASC Topic No. 915-10-05, without any revenue and devotes substantially all of its efforts negotiating & acquiring ownership interests in companies with advanced product development. All losses accumulated since October 21, 2009 have been considered as part of the Company's development stage activities.
	PRINCIPLES OF CONSOLIDATION
	The accompanying condensed consolidated financial statements represent the consolidated financial position and results of operations of the Company and include the accounts and results of operations of the Company and its subsidiaries. The accompanying condensed consolidated financial statements include the parent entity of DoMark International, Inc. and its wholly owned subsidiaries, DOMark Canada, Inc., Solarwerks, Inc., MuscleFoot, Inc. The Company has relied upon the guidance provided by ASC Topic No. 810-10-15-3.
	Foreign Currency Translation and Transaction Gains and Losses
	We record foreign currency translation adjustments and transaction gains and losses in accordance with SFAS 52, Foreign Currency Translation. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ deficit. The Company and its subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of income related to the recurring measurement and settlement of such transactions. The translation rates as of February 28, 2014 were $1US to $.90 Canadian.
	USE OF ESTIMATES
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
	The primary management estimates included in these condensed consolidated financial statements are the fair value of Company stock tendered in various non-monetary transactions and the fair value of the derivative liability for convertible notes payable.
	CASH AND CASH EQUIVALENTS
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At February 28, 2014 there weren’t any cash or cash equivalents. At May 31, 2013, cash and cash equivalents consisted only of cash in the bank.
	LOANS RECEIVABLE CONSULTANT
	The loan receivable consultants is a short term, less than one year note, due July 15, 2014, non-interest bearing
	NET LOSS PER COMMON SHARE
	Basic net loss per common share is computed by dilutive net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially dilutive securities (such as convertible notes payable, convertible preferred stock, and warrants) outstanding during the relevant period. Dilutive securities having an anti-dilutive effect on diluted net loss per common share are excluded from the calculation.
	For the nine months ended February 28, 2014 and 2013, diluted common shares outstanding excluded the following dilutive securities as the effect of their inclusion was anti-dilutive:
		Common Shares Equivalent
		Nine Months Ended February 28,
		2014		2013
	Convertible notes payable		307,459,536		2,163,265
	Series A convertible preferred stock		50,000,000		50,000,000
	Warrants		850,000		850,000
	Total common shares equivalent		358,309,536		53,013,265
	INTANGIBLE ASSETS
	Intangible assets are carried at cost less accumulated amortization. Amortization is recorded over the estimated useful lives of the respective assets.
	RECLASSIFICATION
	A reclassification has been made to the prior period comparative condensed consolidated financial statements to conform to the current period presentation. This reclassification had no effect on previous reported results of operations or financial position. The Company reclassified the amount of treasury stock from the Common stock in balance sheet and statement of equity.
	IMPAIRMENT OF LONG-LIVED ASSETS
	In accordance with ASC Topic No. 360-10-40, long-lived assets, such as property, plant, and equipment, and purchased intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Goodwill and other intangible assets are tested for impairment annually. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
	STOCK-BASED COMPENSATION
	The Company accounts for share based payments in accordance with ASC Topic No. 718, Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on the grant date fair value of the award. In accordance with ASC 718-10-30-9, Measurement Objective - Fair Value at Grant Date, the Company estimates the fair value of the award using a valuation technique. For stock options, the Company uses the Black-Scholes option pricing model. The Company believes this model provides the best estimate of fair value due to its ability to incorporate inputs that change over time, such as volatility and interest rates, and to allow for actual exercise behavior of option holders. Compensation cost is recognized over the requisite service period which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock.
	ASC Topic No. 505, "Compensation-Stock Compensation", establishes standards for the accounting for transactions in which an entity exchanges its equity instruments to non-employees for goods or services. Under this method, stock compensation expense includes compensation expense for all stock-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 505.
	RESEARCH AND DEVELOPMENT
	All research and development expenditures are expensed as incurred.
	REVENUE RECOGNITION
	The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and acceptance has occurred or service has been rendered, the price is fixed or determinable, and collection of the resulting receivable is reasonably assured.

Investments

Investments	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 5 - Investments	'
	Investments consist of:
		February 28,		May 31,
		2014		2013
	Imagic Ltd. - 40% equity interest	$	1,118,308	$	-
	Barefoot Science Products & Services Inc. - 15% equity interest		5,000		5,000
	Total	$	1,123,308	$	5,000
	The cost of the 40% equity interest in Imagic Ltd. at February 28, 2014 consists of:
	July 22, 2013 issuance of 7,500,000 shares of DoMark common stock to Imagic Ltd.	$	697,500
	December 3, 2013 issuance of 8,000,000 shares of DoMark common stock to Meadow Grove Ltd. in exchange for 9% equity interest in Imagic Ltd.		99,200
	Cash payments to or for the benefit of Imagic Ltd.		171,608
	Payments from Foremark Holdings to Imagic Ltd. in exchange for DoMark notes payable to Foremark Holdings		150,000
	Total	$	1,118,308
	Imagic is a privately owned company registered in Gibraltar which owns proprietary product designs for its Digilink and Game Control products. Imagic shares are not quoted or traded on any securities exchange or in any recognized over-the counter market. Imagic is accounted for on the equity method of accounting. The Company consolidates entities that we control. The Company accounts for investments in joint ventures using the equity method of accounting when we exercise significant influence over the venture. If the Company does not exercise significant influence, we account for the investment using the cost method of accounting. Imagic did not have any revenues or expenses for the period ended February 28, 2014.
	On January 25, 2013, the Company executed an agreement with Barefoot Science Products & Services Inc. (“Barefoot Science”) which cancelled the Marketing and Distribution Agreement dated June 20, 2012 and which provided the Company a 15% equity interest in Barefoot Science. As a result, the Company recognized an impairment charge of $4,605,480 in the year ended May 31, 2013 to write off the remaining unamortized prepaid license fees at February 28, 2013 ($4,605,480) and to record the estimated fair value of the 15% equity interest in Barefoot Science at $5,000. Barefoot Science has developed a patented foot strengthening system through insertion of an insole system or by incorporation right into the design of shoes. Barefoot Science shares are not quoted or traded on any securities exchange or in any recognized over-the counter market. Accordingly, it is not practicable to estimate the fair value of this investment.

Licensing_Agreement_With_Wazza

Licensing Agreement With Wazzamba Sa	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 6 - Licensing Agreement With Wazzamba Sa	'
	During the three months ended February 28, 2014, the Company executed a Licensing Agreement with Wazzamba SA (the “Licensor”). The agreement provides the Company an exclusive license to use certain technology (which permits third-party subscribers to integrate a fully equipped online shop into their websites) in Canada and the United States for an initial term ending July 31, 2015. The agreement provides for the Company to pay the Licensor “Flat Fee” compensation of $ 300,000 in 3 installments of $100,000 each (first installment payable within 5 days of the signing of the agreement, second installment payable on July 1, 2014, and third installment payable on February 1, 2015) plus “Revenue Share” compensation equal to 50% of Net Commissions generated by the Company payable monthly. In the event that the Company does not generate $500,000 in Net Commissions by January 31, 2015, the Licensor has the right to cancel the agreement with one month notice (in which case the third $100,000 installment will no longer be due). With respect to an Extended License Term after July 31, 2015, the agreement provides the Company a right of first refusal to match any offer received by the Licensor from a third party.
	At February 28, 2014, the Company recorded an intangible asset for “Licensing Agreement with Wazzamba SA” in the amount of $300,000, and included the liability under the Licenses net of accumulated amortization. Commencing March 1, 2014, the Company will amortize the $300,000 intangible asset on a straight line basis over the remaining 17 months of the Initial Term ending July 31, 2015 (approximately $17,647 per month).
	On March 27, 2014, the Company paid $25,000 of the first $100,000 “Flat Fee” installment due the Licensor under the agreement. The other $75,000 due is presently past due.
	Licenses, net of accumulated amortization are as follows:
		February 28,			May 31,
		2014			2013
	Wazzamba, S.A .	$	300,000		$	-
	Bioharmonics		10,000			10,000
	Subtotal		310,000			10,000
	Accumulated amortization		(2,898	)		(1,828	)
	Total	$	307,102		$	8,182

Note_Payable_To_Bank

Note Payable To Bank	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 7 - Note Payable To Bank	'
	In December 2013, the Company entered into a Loan Agreement with a bank located in Maryland. The related Promissory Note in the amount of $180,000 bears interest at a rate at 10% payable monthly, is due in full on December 31, 2014, and is secured by a Common Stock Reserve (as defined in the Loan Agreement), a Guaranty of Payment from the Company’s chief financial officer and his wife, and certain real property owned by the Company’s chief financial officer and his wife.

Loans_Payable_to_Consultants_a

Loans Payable to Consultants and Stockholders	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 8 - Loans Payable to Consultants and Stockholders	'
	Loans payable to consultants and stockholders consist of:
		February 28,		May 31,
		2014		2013
	Consultant and stockholder	$	79,800	$	7,800
	President of DoMark		49,000		-
	Chairman of Barefoot Science and affiliate		33,500		-
	Consultant		26,996		-
	Consultant		16,097		37,488
	Consultant		2,602		-
	Total	$	207,995	$	45,288
	The loans are informal and do not provide for interest or a stated maturity date.

Convertible_Notes_Payable

Convertible Notes Payable	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 9 - Convertible Notes Payable	'
	At February 28, 2014, convertible notes payable consisted of
	Date of Note		Noteholder	Interest Rate			Maturity date	Principal Amount			Unamortized Debt Discount		Net Carrying Amount
	8/5/13		JSJ Investments, Inc.		10	%	2/5/14	$	7,850	(a)	$	-	$	7,850
	8/7/13		JMJ Financial Inc.		12	%	8/7/14		27,200	(b)		20,670		6,530
	8/13/13		Black Mountain Equities, Inc.		10	%	5/13/14		45,500	(c)		34,342		11,158
	8/26/13		Redwood Fund III		12	%	2/28/14		95,000	(d)		211		94,789
	9/10/13		Asher Enterprises, Inc.		8	%	6/10/14		32,500	(e)		30,990		1,510
	10/9/13		JSJ Investments, Inc.		10	%	4/9/14		25,000	(f)		-		25,000
	10/31/13		Iconic Holdings, LLC		10	%	10/31/14		30,000	(g)		29,735		265
	11/8/13		Iconic Holdings, LLC		10	%	11/8/14		30,000	(g)		29,735		265
	11/26/13		Asher Enterprises, Inc.		8	%	8/26/14		42,500	(h)		19,780		22,720
	12/4/13		LG Capital		10	%	6/4/14		50,000	(g)		49,636		364
	12/9/13		JMJ Financial Inc.		12	%	12/9/14		50,000	(i)		49,909		91
	12/13/13		Gel Properties Inc.		10	%	9/2/14		35,000	(j)		31,670		3,330
	1/10/14		Asher Enterprises, Inc.		8	%	10/2/14		37,500	(k)		24,616		12,884
	2/13/14		JMJ Financial Inc.		12	%	2/13/15		50,000	(b)		49,969		31
	2/13/14		Asher Enterprises, Inc.		8	%	11/13/14		27,500	(l)		27,469		31
	2/19/14		Iconic Holdings, LLC		10	%	2/19/15		30,000	(g)		29,969		31
	2/28/14		LG Capital		8	%	2/28/15		30,000	(g)		30,000		-
	Totals							$	645,550		$	458,701	$	186,849
	Legend
	(a)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.081 or 50% of the average of the three lowest closing prices during the 10 trading days prior to the notice of conversion.
	(b)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.085 or 60% of the lowest closing price during the 25 trading days prior to the notice of conversion.
	(c)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.08 or 50% of the lowest closing price during the 10 trading days prior to the notice of conversion.
	(d)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.0725 or 34% of the lowest closing price during the 20 trading days prior to the notice of conversion.
	(e)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 55% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
	(f)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.00929 or 50% of the average of the three lowest trading prices during the 10 trading days prior to the notice of conversion.
	(g)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 25% of the lowest trading price during the 20 trading days prior to the notice of conversion.
	(h)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 58% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
	(i)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 40% of the lowest closing price during the 25 trading days prior to the notice of conversion.
	(j)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 40% of the lowest closing price during the 20 trading days prior to the notice of conversion.
	(k)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 58% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
	(l)	At noteholder’s option, the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 49% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.

Stockholders_Equity

Stockholders Equity	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 10 - Stockholders Equity	'
	Series A Convertible Preferred Stock
	Each share of Series A Convertible Preferred Stock has 1,000 voting rights and is convertible into 1,000 shares of common stock.
	Common Stock Issuances
	On June 17, 2013, the Company issued 2,500,000 shares of common stock in satisfaction of a $50,000 loan payable.
	On June 29, 2013, the Company issued 2,500,000 shares of common stock (valued at $250,000) to a consultant for services rendered.
	On July 5, 2013, the Company issued 250,000 shares of common stock (valued at $22,500) to a consultant for website development services.
	On July 9, 2013, the Company issued 75,000 shares of common stock (valued at $6,675) to a consultant for services rendered.
	On July 17, 2013, the Company issued 500,000 shares of common stock (valued at $41,650) to a consultant for investor relations services.
	On July 22, 2013, the Company issued 2,874,550 shares of common stock in satisfaction of a $57,491 loan payable.
	On July 22, 2013, the Company issued 7,500,000 shares of common stock (valued at $697,500) in connection with the acquisition of a 19% equity interest in Imagic Ltd. See Note 5.
	On August 15, 2013, the Company issued 500,000 shares of common stock (valued at $35,500) to Bioharmonics Technologies Corp. in connection with the acquisition of certain inventions and related patents and patent applications.
	On August 26, 2013, the Company issued 2,000,000 shares of common stock (valued at $133,000) to a consultant for services rendered.
	On August 28, 2013, the Company issued 1,114,206 shares of common stock to Asher Enterprises, inc. in satisfaction of $14,000 principal amount of convertible notes payable and $26,000 of fees.
	On September 18, 2013, the Company issued 856,164 shares of common stock to Asher Enterprises, Inc. in satisfaction of $25,000 principal amount of convertible notes payable.
	On October 9, 2013, the Company issued 1,000,000 shares of common stock (valued at $45,600) to a consultant firm for investor relation services rendered.
	On October 10, 2013, the Company issued 250,000 shares of common stock (valued at $12,500) to a consultant for services rendered.
	On November 4, 2013, the Company issued 903,261 shares of common stock to Asher Enterprises, Inc. in satisfaction of $14,500 principal amount of convertible notes payable and $500 of costs.
	On November 4, 2013, the Company issued 1,153,846 shares of common stock to Asher Enterprises, Inc. in satisfaction of $15,000 principal amount of principal amount of convertible notes payable.
	On November 7, 2013, the Company issued 3,500,000 shares of common stock in satisfaction of a $52,500 loan payable.
	On November 12, 2013, the Company issued 1,630,435 shares of common stock to Asher Enterprises, Inc. in satisfaction of $15,000 principal amount of convertible notes payable.
	On November 14, 2013, the Company issued 3,999,200 shares of common stock to Iconic Holdings, LLC in satisfaction of $13,197 principal amount of convertible notes payable.
	On November 15, 2013 the Company issued 175,000 shares of common stock (valued at $1,750) to a consultant for services rendered.
	On November 19, 2013, the Company issued 3,456,597 shares of common stock to Asher Enterprises, Inc. in satisfaction of $20,055 principal amount of convertible notes payable and $17,548 of costs.
	On November 19, 2013, the Company issued 8,850,572 shares of common stock to Iconic Holdings, LLC in satisfaction of $22,126 principal amount of convertible notes payable.
	Effective December 3, 2013, the Company issued 8,000,000 shares of common stock (valued at $99,200) to Meadow Grove Ltd. in connection with the acquisition of a 9% equity interest in Imagic Ltd. See Note 5.
	On December 4, 2013, the Company issued 7,072,457 shares of common stock to Iconic Holdings, LLC in satisfaction of $14,852 principal amount of convertible notes payable.
	On December 18, 2013, the Company issued 5,445,005 shares of common stock to Iconic Holdings, LLC in satisfaction of $11,435 principal amount of convertible notes payable.
	On December 26, 2013 the Company issued 4,166,667 shares of common stock to Asher Enterprises, Inc. in satisfaction of $20,000 principal amount of convertible notes payable.
	On December 30, 2013, the Company issued 4,791,667 shares of common stock to Asher Enterprises, Inc. in satisfaction of $23,000 principal amount of convertible notes payable.
	On January 6, 2014, the Company issued 1,305,556 shares of common stock to Asher Enterprises, Inc. in satisfaction of $7,050 principal amount of convertible notes payable.
	On January 13, 2014, the Company issued 6,198,762 shares of common stock to Iconic Holdings, LLC in satisfaction of $13,017 principal amount of convertible notes payable.
	On January 23, 2014, the Company issued 6,436,781 shares of common stock to Iconic Holdings, LLC in satisfaction of $14,000 principal amount of convertible notes payable.
	On February 3, 2014, the Company issued 7,498,890 shares of common stock to Iconic Holdings, LLC in satisfaction of $14,998 principal amount of convertible notes payable.
	On February 6, 2014, the Company issued 4,900,000 shares of common stock to JSJ Investments, Inc. in satisfaction of $17,150 principal amount of convertible notes payable.
	On February 11, 2014, the Company issued 3,000,000 shares of common stock to JMJ Financial Inc. in satisfaction of $10,800 principal amount of convertible notes payable.
	On February 11, 2014, the Company issued 4,901,960 shares of common stock to Continental Equities, LLC in satisfaction of $20,000 principal amount of convertible notes payable.
	On February 13, 2014, the Company issued 5,000,000 shares of common stock to Black Mountain Equities, Inc. in satisfaction of $15,000 principal amount of convertible notes payable.
	On February 25, 2014, the Company issued 4,000,000 shares of common stock to JMJ Financial Inc. in satisfaction of $12,000 principal amount of convertible notes payable.
	Warrants to Purchase Common Stock
	A summary of warrant activity for the year ended May 31, 2013 and for the nine months ended February 28, 2014 follows:
				Weighted Average Exercise Price
		Number of Warrants
	Outstanding at May 31, 2012		-	$	-
	Granted		850,000		0.42
	Exercised		-		-
	Cancelled		-		-
	Outstanding at May 31, 2013		850,000		0.42
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Outstanding at February 28, 2014		850,000	$	0.42
	Warrants outstanding at February 28, 2014 consist of:
	Date Granted	Number Outstanding		Exercise price		Expiration Date
	25-May-12		100,000	$	1	25-May-15
	12-Jun-12		150,000	$	1	12-Jun-15
	26-Jun-12		100,000	$	1	26-Jun-15
	1-Jan-12		500,000	$	0.01	1-Jan-15
	Totals		850,000

Fair_Value_Measurements_and_De

Fair Value Measurements and Derivative Liabiliity	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 11 - Fair Value Measurements and Derivative Liabiliity	'
	The Company evaluates all of it financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
	Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	During the period ended February 28, 2014 the Company entered into several convertible note agreements. The conversion option and the outstanding common stock warrants on that date which were tainted by the convertible note were classified as derivative liabilities at their fair value on the date of issuance.
	Under ASC-815 the conversion options embedded in the notes payable described in Note 9 require liability classification because they do not contain an explicit limit to the number of shares that could be issued upon settlement.
	As defined in FASB ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).
	The three levels of the fair value hierarchy are as follows:
	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.
	Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date.
	Level 3 - Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.
	Derivative liability — the Company’s derivative liability is classified within Level 3 of the fair value hierarchy.
	The Company uses the Black Scholes Option Pricing Model to value its option based derivatives based upon the following assumptions: dividend yield of -0-%, volatility of 100%, risk free rate varying from 8 to 12 % and an expected term equal to the remaining term of the note.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value as at February 28, 2014.
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability- February 28, 2014		-		-		1,040,197		1,040,197
	Derivative liability- May 31, 2013		-		-		237,578		237,578

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Note 12 - Commitments and Contingencies	'
	License Agreements
	On February 29, 2012, the Company entered into a Memorandum of Agreement with Xiamen Taiyang Neng Gongsi and Michael Franklin. For and in consideration of the payment of an initial license fee of $10,000, and for the future payment of royalties of $5.00 per SolaPad unit sold, Xiamen granted an exclusive worldwide license and joint patent rights to the Company for a solar charging case for IPAD, including IPAD 3. The license under the Agreement expires on December 31, 2018.
	On April 19, 2013, our subsidiary DoMark Canada Inc. executed an agreement with Bioharmonics Technologies Cop. (“Bioharmoniecs”). The agreement provided for the acquisition of certain inventions and related patents and patent applications in exchange for 500,000 shares of DoMark common stock (which was delivered April 19, 2013) and $30,000 cash payable no later than October 17, 2013 (which was satisfied through the delivery of an additional 500,000 shares of DoMark common stock to Bioharmonics on August 15, 2013). The agreement also provides for a royalty obligation payable quarterly to Bioharmonics equal to 10% of the wholesale price for each unit using infrared and solar charging.
	In January 2014, the Company executed a Licensing Agreement with Wazzamba SA. See Note 6.
	Employment Agreements
	On May 25, 2012, the Company entered into an employment agreement with its President, R. Brentwood Strasler, for an indefinite period or until terminated. Mr. Strasler is entitled to an annual salary of $150,000 USD and 100,000 stock purchase warrants exercisable to purchase shares of common stock of the Company at $1.00 per share. The warrants are exercisable for a three year period and can be vested quarterly on a pro rata basis over twelve months from the date of issue. Additionally, Mr. Strasler is to be enrolled in a long term Executive Option Plan and is entitled to term life insurance in the face amount of $2,500,000, payable to the beneficiary designated by Mr. Strasler.
	On June 15, 2012, the Company entered into an employment agreement with its Chief Executive Officer Andrew Ritchie, for an indefinite period or until terminated. Mr. Ritchie is entitled to an annual salary of $240,000 USD and 150,000 stock purchase warrants exercisable to purchase shares of common stock of the Company at $1.00 per share. The warrants are exercisable for a three year period and can be vested quarterly on a pro rata basis over twelve months from the date of issue. Additionally, Mr. Ritchie is to be enrolled in a long term Executive Option Plan and is entitled to term life insurance in the face amount of $2,500,000, payable to the beneficiary designated by Mr. Richie.
	Lease Agreement
	On August 1, 2013, the Company entered into an office lease in Toronto, Ontario, Canada for a five year period. At February 28, 2014, the future lease commitments on this lease for the years ended May 31, are as follows, and are in U.S. dollars:
	2014	$	12,150
	2015		48,600
	2016		48,600
	2017		48,600
	2018		48,600
	Thereafter		8,100
	Total	$	214,650

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Feb. 28, 2014
Summary Of Significant Accounting Policies Policies	'
Recent Accountng Pronouncements	'
	The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. It does not expect the adoption of these pronouncements to have a material impact on its financial position, results of operations or cash flows.
Development Stage Company	'
	The Company is a development stage company as defined in ASC Topic No. 915-10-05, without any revenue and devotes substantially all of its efforts negotiating & acquiring ownership interests in companies with advanced product development. All losses accumulated since October 21, 2009 have been considered as part of the Company's development stage activities.
Principles of Consolidation	'
	The accompanying condensed consolidated financial statements represent the consolidated financial position and results of operations of the Company and include the accounts and results of operations of the Company and its subsidiaries. The accompanying condensed consolidated financial statements include the parent entity of DoMark International, Inc. and its wholly owned subsidiaries, DOMark Canada, Inc., Solarwerks, Inc., MuscleFoot, Inc. The Company has relied upon the guidance provided by ASC Topic No. 810-10-15-3.
Foreign Currency Translation and Transaction Gains and Losses	'
	We record foreign currency translation adjustments and transaction gains and losses in accordance with SFAS 52, Foreign Currency Translation. For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders’ deficit. The Company and its subsidiaries also have transactions in foreign currencies other than the functional currency. We record transaction gains and losses in our consolidated statements of income related to the recurring measurement and settlement of such transactions. The translation rates as of February 28, 2014 were $1US to $.90 Canadian.
Use of Estimates	'
	The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. These estimates and assumptions also affect the reported amounts of revenues, costs and expenses during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
	The primary management estimates included in these condensed consolidated financial statements are the fair value of Company stock tendered in various non-monetary transactions and the fair value of the derivative liability for convertible notes payable.
Cash and Cash Equivalents	'
	The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At February 28, 2014 there weren’t any cash or cash equivalents. At May 31, 2013, cash and cash equivalents consisted only of cash in the bank.
Loans Receivable Consultant	'
	The loan receivable consultants is a short term, less than one year note, due July 15, 2014, non-interest bearing
Net Loss Per Common Share	'
	Basic net loss per common share is computed by dilutive net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially dilutive securities (such as convertible notes payable, convertible preferred stock, and warrants) outstanding during the relevant period. Dilutive securities having an anti-dilutive effect on diluted net loss per common share are excluded from the calculation.
	For the nine months ended February 28, 2014 and 2013, diluted common shares outstanding excluded the following dilutive securities as the effect of their inclusion was anti-dilutive:
		Common Shares Equivalent
		Nine Months Ended February 28,
		2014		2013
	Convertible notes payable		307,459,536		2,163,265
	Series A convertible preferred stock		50,000,000		50,000,000
	Warrants		850,000		850,000
	Total common shares equivalent		358,309,536		53,013,265
Intangible Assets	'
	Intangible assets are carried at cost less accumulated amortization. Amortization is recorded over the estimated useful lives of the respective assets.
Reclassification	'
	A reclassification has been made to the prior period comparative condensed consolidated financial statements to conform to the current period presentation. This reclassification had no effect on previous reported results of operations or financial position. The Company reclassified the amount of treasury stock from the Common stock in balance sheet and statement of equity.
Impairment of Long-Lived Assets	'
	In accordance with ASC Topic No. 360-10-40, long-lived assets, such as property, plant, and equipment, and purchased intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Goodwill and other intangible assets are tested for impairment annually. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.
Stock Based Compensation	'
	The Company accounts for share based payments in accordance with ASC Topic No. 718, Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on the grant date fair value of the award. In accordance with ASC 718-10-30-9, Measurement Objective - Fair Value at Grant Date, the Company estimates the fair value of the award using a valuation technique. For stock options, the Company uses the Black-Scholes option pricing model. The Company believes this model provides the best estimate of fair value due to its ability to incorporate inputs that change over time, such as volatility and interest rates, and to allow for actual exercise behavior of option holders. Compensation cost is recognized over the requisite service period which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock.
	ASC Topic No. 505, "Compensation-Stock Compensation", establishes standards for the accounting for transactions in which an entity exchanges its equity instruments to non-employees for goods or services. Under this method, stock compensation expense includes compensation expense for all stock-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 505.
Research and Development	'
	All research and development expenditures are expensed as incurred.
Revenue Recognition	'
	The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and acceptance has occurred or service has been rendered, the price is fixed or determinable, and collection of the resulting receivable is reasonably assured.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Feb. 28, 2014
Summary Of Significant Accounting Policies Tables	'
Net Loss Per Common Share	'
	For the nine months ended February 28, 2014 and 2013, diluted common shares outstanding excluded the following dilutive securities as the effect of their inclusion was anti-dilutive:
		Common Shares Equivalent
		Nine Months Ended February 28,
		2014		2013
	Convertible notes payable		307,459,536		2,163,265
	Series A convertible preferred stock		50,000,000		50,000,000
	Warrants		850,000		850,000
	Total common shares equivalent		358,309,536		53,013,265

Investments_Tables

Investments (Tables)	9 Months Ended
	Feb. 28, 2014
Investments Tables	'
Investments	'
		February 28,		May 31,
		2014		2013
	Imagic Ltd. - 40% equity interest	$	1,118,308	$	-
	Barefoot Science Products & Services Inc. - 15% equity interest		5,000		5,000
	Total	$	1,123,308	$	5,000
Cost of equity interest	'
	The cost of the 40% equity interest in Imagic Ltd. at February 28, 2014 consists of:
	July 22, 2013 issuance of 7,500,000 shares of DoMark common stock to Imagic Ltd.	$	697,500
	December 3, 2013 issuance of 8,000,000 shares of DoMark common stock to Meadow Grove Ltd. in exchange for 9% equity interest in Imagic Ltd.		99,200
	Cash payments to or for the benefit of Imagic Ltd.		171,608
	Payments from Foremark Holdings to Imagic Ltd. in exchange for DoMark notes payable to Foremark Holdings		150,000
	Total	$	1,118,308

Licensing_Agreement_With_Wazza1

Licensing Agreement With Wazzamba Sa (Tables)	9 Months Ended
	Feb. 28, 2014
Licensing Agreement With Wazzamba Sa Tables	'
Licenses, net of accumulated amortization	'
	Licenses, net of accumulated amortization are as follows:
		February 28,			May 31,
		2014			2013
	Wazzamba, S.A .	$	300,000		$	-
	Bioharmonics		10,000			10,000
	Subtotal		310,000			10,000
	Accumulated amortization		(2,898	)		(1,828	)
	Total	$	307,102		$	8,182

Loans_Payable_to_Consultants_a1

Loans Payable to Consultants and Stockholders (Tables)	9 Months Ended
	Feb. 28, 2014
Loans Payable To Consultants And Stockholders Tables	'
Loans payable to consultants and stockholders	'
	Loans payable to consultants and stockholders consist of:
		February 28,		May 31,
		2014		2013
	Consultant and stockholder	$	79,800	$	7,800
	President of DoMark		49,000		-
	Chairman of Barefoot Science and affiliate		33,500		-
	Consultant		26,996		-
	Consultant		16,097		37,488
	Consultant		2,602		-
	Total	$	207,995	$	45,288

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Feb. 28, 2014
Convertible Notes Payable Tables	'
Convertible notes payable	'
	At February 28, 2014, convertible notes payable consisted of
	Date of Note	Noteholder	Interest Rate			Maturity date	Principal Amount			Unamortized Debt Discount		Net Carrying Amount
	8/5/13	JSJ Investments, Inc.		10	%	2/5/14	$	7,850	(a)	$	-	$	7,850
	8/7/13	JMJ Financial Inc.		12	%	8/7/14		27,200	(b)		20,670		6,530
	8/13/13	Black Mountain Equities, Inc.		10	%	5/13/14		45,500	(c)		34,342		11,158
	8/26/13	Redwood Fund III		12	%	2/28/14		95,000	(d)		211		94,789
	9/10/13	Asher Enterprises, Inc.		8	%	6/10/14		32,500	(e)		30,990		1,510
	10/9/13	JSJ Investments, Inc.		10	%	4/9/14		25,000	(f)		-		25,000
	10/31/13	Iconic Holdings, LLC		10	%	10/31/14		30,000	(g)		29,735		265
	11/8/13	Iconic Holdings, LLC		10	%	11/8/14		30,000	(g)		29,735		265
	11/26/13	Asher Enterprises, Inc.		8	%	8/26/14		42,500	(h)		19,780		22,720
	12/4/13	LG Capital		10	%	6/4/14		50,000	(g)		49,636		364
	12/9/13	JMJ Financial Inc.		12	%	12/9/14		50,000	(i)		49,909		91
	12/13/13	Gel Properties Inc.		10	%	9/2/14		35,000	(j)		31,670		3,330
	1/10/14	Asher Enterprises, Inc.		8	%	10/2/14		37,500	(k)		24,616		12,884
	2/13/14	JMJ Financial Inc.		12	%	2/13/15		50,000	(b)		49,969		31
	2/13/14	Asher Enterprises, Inc.		8	%	11/13/14		27,500	(l)		27,469		31
	2/19/14	Iconic Holdings, LLC		10	%	2/19/15		30,000	(g)		29,969		31
	2/28/14	LG Capital		8	%	2/28/15		30,000	(g)		30,000		-
	Totals						$	645,550		$	458,701	$	186,849

Stockholders_Equity_Tables

Stockholders Equity (Tables)	9 Months Ended
	Feb. 28, 2014
Stockholders Equity Tables	'
Summary of warrant activity	'
	A summary of warrant activity for the year ended May 31, 2013 and for the nine months ended February 28, 2014 follows:
				Weighted Average Exercise Price
		Number of Warrants
	Outstanding at May 31, 2012		-	$	-
	Granted		850,000		0.42
	Exercised		-		-
	Cancelled		-		-
	Outstanding at May 31, 2013		850,000		0.42
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Outstanding at February 28, 2014		850,000	$	0.42
Warrants outstanding	'
	Warrants outstanding at February 28, 2014 consist of:
	Date Granted	Number Outstanding		Exercise price		Expiration Date
	25-May-12		100,000	$	1	25-May-15
	12-Jun-12		150,000	$	1	12-Jun-15
	26-Jun-12		100,000	$	1	26-Jun-15
	1-Jan-12		500,000	$	0.01	1-Jan-15
	Totals		850,000

Fair_Value_Measurements_and_De1

Fair Value Measurements and Derivative Liabiliity (Tables)	9 Months Ended
	Feb. 28, 2014
Notes to Financial Statements	'
Recurring Fair Value Measurements	'
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value as at February 28, 2014.
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability- February 28, 2014		-		-		1,040,197		1,040,197
	Derivative liability- May 31, 2013		-		-		237,578		237,578

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Feb. 28, 2014
Commitments And Contingencies Tables	'
Future Lease Commitments	'
	2014	$	12,150
	2015		48,600
	2016		48,600
	2017		48,600
	2018		48,600
	Thereafter		8,100
	Total	$	214,650

Going_Concern_Details_Narrativ

Going Concern (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		52 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
Going Concern Details Narrative	'	'	'	'	'
Loss from operation	($1,064,054)	($5,781,038)	($2,347,198)	($7,930,191)	($17,800,184)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Feb. 28, 2014	Feb. 28, 2013
Summary Of Significant Accounting Policies Details	'	'
Convertible notes payable	307,459,536	2,163,265
Series A convertible preferred stock	50,000,000	50,000,000
Warrants	850,000	350,000
Total	358,309,536	53,013,265

Investments_Details

Investments (Details) (USD $)	Feb. 28, 2014	31-May-13
Investments Details	'	'
Imagic Ltd. - 40% equity interest	$1,118,308	'
Barefoot Science Products & Services Inc. - 15% equity interest	5,000	5,000
Total	$1,123,308	$5,000

Investments_Details_1

Investments (Details 1) (USD $)	Feb. 28, 2014	31-May-13
Investments Details	'	'
July 22, 2013 issuance of 7,500,000 shares of DoMark common stock to Imagic Ltd.	697,500	'
December 3, 2013 issuance of 8,000,000 shares of DoMark common stock to Meadow Grove Ltd. in exchange for 9% equity interest in Imagic Ltd.	99,200	'
Cash payments to or for the benefit of Imagic Ltd.	$171,608	'
Payments from Foremark Holdings to Imagic Ltd. in exchange for DoMark notes payable to Foremark Holdings	150,000	'
Total	$1,118,308	'

Investments_Details_Narrative

Investments (Details Narrative) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended	52 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014	Feb. 28, 2013	31-May-13	Feb. 28, 2014
Investments Details Narrative	'	'	'	'	'	'
Impairment charge	'	$4,605,480	'	$4,605,480	$4,605,480	$4,605,480

Licensing_Agreement_With_Wazza2

Licensing Agreement With Wazzamba Sa (Details) (USD $)	Feb. 28, 2014	31-May-13
Licensing Agreement With Wazzamba Sa Details	'	'
Wazzamba, S.A.	$300,000	'
Bioharmonics	10,000	10,000
Subtotal	310,000	10,000
Accumulated amortization	-2,898	-1,828
Total	$307,102	$8,182

Loans_Payable_to_Consultants_a2

Loans Payable to Consultants and Stockholders (Details) (USD $)	Feb. 28, 2014	31-May-13
Loans payable to consultants and stockholders	$207,995	$29,088
Consultant And Stockholder [Member]	'	'
Loans payable to consultants and stockholders	79,800	7,800
Chairman of DoMark [Member]	'	'
Loans payable to consultants and stockholders	49,000	'
Chairman Of Barefoot Science And Affiliate [Member]	'	'
Loans payable to consultants and stockholders	33,500	'
Consultant [Member]	'	'
Loans payable to consultants and stockholders	26,996	'
Consultant One [Member]	'	'
Loans payable to consultants and stockholders	16,097	37,488
Consultant Two [Member]	'	'
Loans payable to consultants and stockholders	$2,602	'

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Details) (USD $)	Feb. 28, 2014		31-May-13
Principal Amount	$645,550		'
Unamortized Debt Discount	458,701		59,301
Net Carrying Amount	186,849		148,691
JSJ Investments Inc. [Member]	'		'
Date of Note	'2013-08-05		'
Interest Rate	10.00%		'
Maturity date	'2014-02-05		'
Principal Amount	7,850	[1]	'
Unamortized Debt Discount	'		'
Net Carrying Amount	7,850		'
JMJ Financial Inc. [Member]	'		'
Date of Note	'2013-08-07		'
Interest Rate	12.00%		'
Maturity date	'2014-08-07		'
Principal Amount	27,200	[2]	'
Unamortized Debt Discount	20,670		'
Net Carrying Amount	6,530		'
Black Mountain Equities Inc. [Member]	'		'
Date of Note	'2013-08-13		'
Interest Rate	10.00%		'
Maturity date	'2014-05-13		'
Principal Amount	45,500	[3]	'
Unamortized Debt Discount	34,342		'
Net Carrying Amount	11,158		'
Redwood Fund III [Member]	'		'
Date of Note	'2013-08-26		'
Interest Rate	12.00%		'
Maturity date	'2014-02-28		'
Principal Amount	95,000	[4]	'
Unamortized Debt Discount	211		'
Net Carrying Amount	94,789		'
Asher Enterprises Inc. [Member]	'		'
Date of Note	'2013-09-10		'
Interest Rate	8.00%		'
Maturity date	'2014-06-10		'
Principal Amount	32,500	[5]	'
Unamortized Debt Discount	30,990		'
Net Carrying Amount	1,510		'
JSJ Investments Inc. One [Member]	'		'
Date of Note	'2013-10-09		'
Interest Rate	10.00%		'
Maturity date	'2014-04-09		'
Principal Amount	25,000	[6]	'
Unamortized Debt Discount	'		'
Net Carrying Amount	25,000		'
Iconic Holdings, LLC [Member]	'		'
Date of Note	'2013-10-31		'
Interest Rate	10.00%		'
Maturity date	'2014-10-31		'
Principal Amount	30,000	[7]	'
Unamortized Debt Discount	29,735		'
Net Carrying Amount	265		'
Iconic Holdings, LLC One [Member]	'		'
Date of Note	'2013-11-08		'
Interest Rate	10.00%		'
Maturity date	'2014-11-08		'
Principal Amount	30,000	[7]	'
Unamortized Debt Discount	29,735		'
Net Carrying Amount	265		'
Asher Enterprises Inc One [Member]	'		'
Date of Note	'2013-11-26		'
Interest Rate	8.00%		'
Maturity date	'2014-08-26		'
Principal Amount	42,500	[8]	'
Unamortized Debt Discount	19,780		'
Net Carrying Amount	22,720		'
LG Capital [Member]	'		'
Date of Note	'2013-12-04		'
Interest Rate	10.00%		'
Maturity date	'2014-06-04		'
Principal Amount	50,000	[7]	'
Unamortized Debt Discount	49,636		'
Net Carrying Amount	364		'
JMJ Financial Inc One [Member]	'		'
Date of Note	'2013-12-09		'
Interest Rate	12.00%		'
Maturity date	'2014-12-09		'
Principal Amount	50,000	[9]	'
Unamortized Debt Discount	49,909		'
Net Carrying Amount	91		'
Gel Properties Inc [Member]	'		'
Date of Note	'2013-12-13		'
Interest Rate	10.00%		'
Maturity date	'2014-09-02		'
Principal Amount	35,000	[10]	'
Unamortized Debt Discount	31,670		'
Net Carrying Amount	3,330		'
Asher Enterprises Inc. Two [Member]	'		'
Date of Note	'2014-01-10		'
Interest Rate	8.00%		'
Maturity date	'2014-10-02		'
Principal Amount	37,500	[11]	'
Unamortized Debt Discount	24,616		'
Net Carrying Amount	12,884		'
JMJ Financial Inc Two [Member]	'		'
Date of Note	'2014-02-13		'
Interest Rate	12.00%		'
Maturity date	'2015-02-13		'
Principal Amount	50,000	[2]	'
Unamortized Debt Discount	49,969		'
Net Carrying Amount	31		'
Asher Enterprises Inc. Three [Member]	'		'
Date of Note	'2014-02-13		'
Interest Rate	8.00%		'
Maturity date	'2014-11-13		'
Principal Amount	27,500	[12]	'
Unamortized Debt Discount	27,469		'
Net Carrying Amount	31		'
Iconic Holdings, LLC Two [Member]	'		'
Date of Note	'2014-02-19		'
Interest Rate	10.00%		'
Maturity date	'2015-02-19		'
Principal Amount	30,000	[7]	'
Unamortized Debt Discount	29,969		'
Net Carrying Amount	31		'
LG Capital One [Member]	'		'
Date of Note	'2014-02-28		'
Interest Rate	8.00%		'
Maturity date	'2015-02-28		'
Principal Amount	30,000	[7]	'
Unamortized Debt Discount	30,000		'
Net Carrying Amount	'		'
[1]	(a) At noteholders option the principal amount and accrued interest are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.081 or 50% of the average of the three lowest closing prices during the 10 trading days prior to the notice of conversion.
[2]	(b) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.085 or 60% of the lowest closing price during the 25 trading days prior to the notice of conversion.
[3]	(c) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.08 or 50% of the lowest closing price during the 10 trading days prior to the notice of conversion.
[4]	(d) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.0725 or 34% of the lowest closing price during the 20 trading days prior to the notice of conversion.
[5]	(e) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 55% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
[6]	(f) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to the lower of $0.00929 or 50% of the average of the three lowest trading prices during the 10 trading days prior to the notice of conversion.
[7]	(g) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 25% of the lowest trading price during the 20 trading days prior to the notice of conversion.
[8]	(h) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 58% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
[9]	(i) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 40% of the lowest closing price during the 25 trading days prior to the notice of conversion.
[10]	(j) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 40% of the lowest closing price during the 20 trading days prior to the notice of conversion.
[11]	(k) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 58% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.
[12]	(l) At noteholders option the principal amount (and accrued interest) are convertible into shares of DoMark common stock at a conversion price equal to 49% of the average of the two lowest closing prices during the 15 trading days prior to the notice of conversion.

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	9 Months Ended	12 Months Ended
	Feb. 28, 2014	31-May-13
Stockholders Equity Details	'	'
Outstanding Number of Warrants, Beginning Balance	850,000	850,000
Granted	'	'
Exercised	'	'
Cancelled	'	'
Outstanding Number of Warrants, Ending Balance	850,000	850,000
Weighted Average Exercise Price, Beginning Balance	$0.42	$0.42
Granted	'	'
Exercised	'	'
Cancelled	'	'
Weighted Average Exercise Price, Ending Balance	$0.42	$0.42

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	Feb. 28, 2014	31-May-13	31-May-12
Number Of Warrant Outstanding	850,000	850,000	850,000
Warrant [Member]	'	'	'
Date Granted	25-May-12	'	'
Number Of Warrant Outstanding	100,000	'	'
Exercise price	1	'	'
Expiration Date	25-May-15	'	'
Warrant One [Member]	'	'	'
Date Granted	12-Jun-12	'	'
Number Of Warrant Outstanding	150,000	'	'
Exercise price	1	'	'
Expiration Date	12-Jun-15	'	'
Warrant Two [Member]	'	'	'
Date Granted	26-Jun-12	'	'
Number Of Warrant Outstanding	100,000	'	'
Exercise price	1	'	'
Expiration Date	26-Jun-15	'	'
Warrant Three [Member]	'	'	'
Date Granted	1-Jan-12	'	'
Number Of Warrant Outstanding	500,000	'	'
Exercise price	0.01	'	'
Expiration Date	1-Jan-15	'	'

Fair_Value_Measurements_and_De2

Fair Value Measurements and Derivative Liabiliity (Details) (USD $)	Feb. 28, 2014
LIABILITIES	'
Derivative liability- February 28, 2014	$1,040,197
Derivative liability- May 31, 2013	237,578
Level 1 [Member]	'
LIABILITIES	'
Derivative liability- February 28, 2014	'
Derivative liability- May 31, 2013	'
Level 2 [Member]	'
LIABILITIES	'
Derivative liability- February 28, 2014	'
Derivative liability- May 31, 2013	'
Level 3 [Member]	'
LIABILITIES	'
Derivative liability- February 28, 2014	1,040,197
Derivative liability- May 31, 2013	$237,578

Recovered_Sheet1

Commitments And Contingencies (Details) (USD $)	Feb. 28, 2014
Commitments And Contingencies Details	'
2014	$12,150
2015	48,600
2016	48,600
2017	48,600
2018	48,600
Thereafter	8,100
Total	$214,650